Bicyclic 1,4-Diazepanones and Therapeutic Uses
Summary
The USPTO published patent application US20260098018A1 disclosing bicyclic 1,4-diazepanone compounds of formula (I) and their therapeutic uses for treating diseases responsive to modulation of skeletal sarcomere contractility. The application names 15 inventors and was filed July 7, 2025 under Application No. 19261878.
What changed
The USPTO published a patent application disclosing novel bicyclic 1,4-diazepanone compounds of formula (I), including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, along with pharmaceutical compositions and methods of using these compounds to treat diseases and disorders responsive to modulation of skeletal sarcomere contractility.
Pharmaceutical companies, biotech firms, and generic drug manufacturers should monitor this publication for freedom-to-operate considerations and competitive landscape implications. The disclosure provides technical details on compound structures and therapeutic applications that may inform R&D decisions and patent strategy planning.
What to do next
- Monitor for updates
- Review patent claims for freedom to operate analysis
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF
Application US20260098018A1 Kind: A1 Apr 09, 2026
Inventors
Bradley P. MORGAN, Chris EVANS, Pu-Ping LU, Makoto YAMASAKI, Wenyue WANG, Scott COLLIBEE, Takuya MAKINO, Kazuyuki TSUCHIYA, Toshio KUROSAKI, Susumu YAMAKI, Eriko HONJO, Yuka KOIZUMI, Naoto KATOH, Ryuichi SEKIOKA, Ikumi KURIWAKI
Abstract
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.
CPC Classifications
C07D 243/14 C07D 401/12 C07D 403/14 C07D 405/14 C07D 413/08 C07D 413/12 C07D 417/12 C07D 471/04 C07D 471/10 C07D 487/04 C07D 498/04 C07D 519/00 C07B 2200/13
Filing Date
2025-07-07
Application No.
19261878
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.